(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) for zongertinib to treat unresectable or metastatic non-small cell lung ...

INGELHEIM, Germany and PLEASANTON, Calif., March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the project ...

In the last 5 years, P Paggiaro has received institutional support for educational and research activities from: AstraZeneca, Boehringer Ingelheim ... No writing assistance was utilized in ...

International assistance has historically played a significant role in implementing U.S. foreign policy. In the aftermath of World War II, the Marshall Plan provided a vital lifeline to Western Europe ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rachel Cericola Rachel Cericola is a writer covering smart home. In ...